Pablo Conesa-Zamora

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7271686/publications.pdf

Version: 2024-02-01

68 papers	1,351 citations	361045 20 h-index	377514 34 g-index
73 all docs	73 docs citations	73 times ranked	2079 citing authors

#	Article	IF	Citations
1	Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigenâ€Based Tumor Immune Response. Global Challenges, 2022, 6, 2100051.	1.8	0
2	Pharmacogenetic role of vitamin D-binding protein and vitamin D receptor polymorphisms in the treatment response of dialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2022, 37, 792-795.	0.4	2
3	Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment. Cancers, 2022, 14, 3248.	1.7	6
4	Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. Journal of Infection, 2021, 82, e40-e42.	1.7	52
5	The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. Cancers, 2021, 13, 861.	1.7	23
6	The effect of fascin 1 inhibition on head and neck squamous cell carcinoma cells. European Journal of Oral Sciences, 2021, , .	0.7	2
7	Relationship between polymorphisms in the FAS/FASL death receptor system and progression of low-grade precursor lesions infected with high-risk human papilloma virus. Human Immunology, 2021, 82, 621-624.	1.2	0
8	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. Frontiers in Immunology, 2021, 12, 672255.	2.2	6
9	Global Methylome Scores Correlate with Histological Subtypes of Colorectal Carcinoma and Show Different Associations with Common Clinical and Molecular Features. Cancers, 2021, 13, 5165.	1.7	0
10	miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route. Mutagenesis, 2020, 35, 233-241.	1.0	5
11	Predictive values of colon microbiota in the treatment response to colorectal cancer. Pharmacogenomics, 2020, 21, 1045-1059.	0.6	4
12	Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor. International Journal of Molecular Sciences, 2020, 21, 1991.	1.8	6
13	New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells. Experimental and Molecular Medicine, 2020, 52, 281-292.	3.2	40
14	Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells. Journal of Molecular Medicine, 2020, 98, 383-394.	1.7	18
15	ColPortal, an integrative multiomic platform for analysing epigenetic interactions in colorectal cancer. Scientific Data, 2019, 6, 255.	2.4	9
16	Differences in gene expression profiling and biomarkers between histological colorectal carcinoma subsets from the serrated pathway. Histopathology, 2019, 75, 496-507.	1.6	6
17	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. Pharmacogenomics Journal, 2019, 19, 83-96.	0.9	10
18	Differences in expression profiling and biomarkers between histological colorectal carcinoma[s] subsets from the serrated pathway. Annals of Oncology, 2018, 29, vi23.	0.6	0

#	Article	IF	Citations
19	Two histologically colorectal carcinomas subsets from the serrated pathway show different methylome signatures and diagnostic biomarkers. Clinical Epigenetics, 2018, 10, 141.	1.8	12
20	Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge. BioMed Research International, 2018, 2018, 1-9.	0.9	1
21	A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF. International Journal of Medical Sciences, 2018, 15, 10-15.	1.1	36
22	THU0010â€...Polymorphisms in phase i-metabolising enzyme and hormone receptor genes influence the response to anti-tnf therapy. , 2018, , .		0
23	Reasons for Discontinuation and Adverse Effects of TNFÎ± Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. Annals of Pharmacotherapy, 2017, 51, 388-393.	0.9	14
24	Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenetics and Genomics, 2017, 27, 70-77.	0.7	5
25	MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9. Oncogenesis, 2017, 6, 399.	2.1	74
26	BARHL1 Is Downregulated in Alzheimerâ€™s Disease and May Regulate Cognitive Functions through ESR1 and Multiple Pathways. Genes, 2017, 8, 245.	1.0	57
27	Genotyping of six clopidogrel-metabolizing enzyme polymorphisms has a minor role in the assessment of platelet reactivity in patients with acute coronary syndrome. Anatolian Journal of Cardiology, 2017, 17, 303-312.	0.5	3
28	Thrombus Aspirated from Patients with ST-Elevation Myocardial Infarction: Association between 3-Nitrotyrosine and Inflammatory Markers - Insights from ARTERIA Study. International Journal of Medical Sciences, 2016, 13, 477-482.	1.1	3
29	HIF-1Î± expression and high microvessel density are characteristic features in serrated colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 395-404.	1.4	11
30	A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients. American Journal of Hematology, 2016, 91, E305-7.	2.0	6
31	Biomarkers for the identification of precursor polyps of colorectal serrated adenocarcinomas. Cellular Oncology (Dordrecht), 2016, 39, 243-252.	2.1	8
32	Methylome profiling reveals functions and genes which are differentially methylated in serrated compared to conventional colorectal carcinoma. Clinical Epigenetics, 2015, 7, 101.	1.8	21
33	PEG-Interferon-Î± ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study. Farmacia Hospitalaria, 2015, 39, 29-43.	0.6	1
34	Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Annals of Hematology, 2014, 93, 243-247.	0.8	13
35	Role of Genetic Polymorphisms in NFKB-Mediated Inflammatory Pathways in Response to Primary Chemoradiation Therapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 595-602.	0.4	15
36	Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma. International Journal of Cancer, 2013, 132, 297-307.	2.3	43

#	Article	IF	Citations
37	Influence of polymorphisms and TNF and IL1Î² serum concentration on the infliximab response in Crohnâ€™s disease and ulcerative colitis. European Journal of Clinical Pharmacology, 2013, 69, 431-438.	0.8	77
38	Evaluation of the association of NKG2C copy number variations with susceptibility to human papillomavirus-induced cervical lesions. Human Immunology, 2013, 74, 1352-1356.	1.2	5
39	Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study. BMC Cancer, 2013, 13, 228.	1.1	13
40	Immune responses against virus and tumor in cervical carcinogenesis: Treatment strategies for avoiding the HPV-induced immune escape. Gynecologic Oncology, 2013, 131, 480-488.	0.6	42
41	Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell-cycle markers and HPV presence. Experimental and Molecular Pathology, 2013, 95, 151-155.	0.9	16
42	Microsatellite pathologic score does not efficiently identify high microsatellite instability in colorectal serrated adenocarcinoma. Human Pathology, 2013, 44, 759-765.	1.1	7
43	Pharmacotherapeutic Follow-up and Pharmacogenetics of CYP2C9 and CYP3A4 in Antihypertensive Therapy: A Pilot Study in a Community Pharmacy. Therapeutic Innovation and Regulatory Science, 2013, 47, 489-494.	0.8	2
44	Inflammatory markers in blood and thrombus aspirated from patients with acute myocardial infarction with st-segment elevation: ARTERIA trial study design and rationale. Biomarkers, 2013, 18, 369-372.	0.9	3
45	Role of Cell Cycle Biomarkers in Human Papillomavirus Related Uterine Lesions. Current Pharmaceutical Design, 2013, 19, 1412-1424.	0.9	7
46	Role of cell cycle biomarkers in human papillomavirus related uterine lesions. Current Pharmaceutical Design, 2013, 19, 1412-24.	0.9	8
47	Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine, 2012, 79, 591-596.	0.8	63
48	Immunohistochemical expression profile of Î²-catenin, E-cadherin, P-cadherin, laminin-5Î³2 chain, and SMAD4 in colorectal serrated adenocarcinoma. Human Pathology, 2012, 43, 1094-1102.	1.1	29
49	Role of GSTT1 and M1 null genotypes as risk factors for Bâ€cell lymphoma: Influence of geographical factors and occupational exposure. Molecular Carcinogenesis, 2012, 51, 508-513.	1.3	9
50	Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSIâ€H carcinomas. International Journal of Cancer, 2012, 131, 1790-1799.	2.3	44
51	Analysis of performance characteristics of five cell cycle-related immunohistochemical markers and human papillomavirus genotyping in the diagnosis of cervical squamous cell carcinoma precursor lesions. , 2012, 34, 49-55.		0
52	Comparison of Allelic Discrimination by dHPLC, HRM, and TaqMan in the Detection of BRAF Mutation V600E. Journal of Molecular Diagnostics, 2011, 13, 467-473.	1.2	33
53	Tumour budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. Histopathology, 2011, 59, 1046-1056.	1.6	46
54	Papel del citocromo P450 en la farmacocinÃ©tica y en la farmacogenÃ©tica de los fÃ¡rmacos antihipertensivos. Farmacia Hospitalaria, 2011, 35, 84-92.	0.6	18

#	Article	IF	Citations
55	Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody. Thrombosis and Haemostasis, 2010, 104, 1143-1149.	1.8	24
56	Expression profiles of ProEx C and Ki67 in squamous cell carcinoma in situ of the skin and their relationship with human papillomavirus genotypes. Journal of Cutaneous Pathology, 2010, 37, 730-736.	0.7	6
57	Human Papillomavirus Genotyping in Histological Sections of Precursor Lesions of Cervical Carcinoma: Its Role as a Possible Adjunct for the Evaluation of the Oncogenic Potential of Specific Human Papillomavirus Genotypes â€“ A Study in a Coastal Region of Southeastern Spain. Gynecologic and Obstetric Investigation, 2010, 70, 113-119.	0.7	5
58	Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma. Human Immunology, 2010, 71, 314-317.	1.2	11
59	Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma. Human Pathology, 2010, 41, 1359-1368.	1.1	89
60	Association between theFCGR3AV158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients. Scandinavian Journal of Rheumatology, 2010, 39, 518-520.	0.6	30
61	Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. Journal of Clinical Pathology, 2009, 62, 159-162.	1.0	19
62	Effect of Human Papillomavirus on Cell Cycleâ€“Related Proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in Precursor Lesions of Cervical Carcinoma. American Journal of Clinical Pathology, 2009, 132, 378-390.	0.4	86
63	Genotype distribution of human papillomavirus (HPV) and co-infections in cervical cytologic specimens from two outpatient gynecological clinics in a region of southeast Spain. BMC Infectious Diseases, 2009, 9, 124.	1.3	25
64	Retinoic Acid as a Modulator of the Activity of Protein Kinase CÎ±. Biochemistry, 2005, 44, 11353-11360.	1.2	17
65	A comparative study of the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine and some homologous compounds on PKCÎ± and PKCÉ›. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1687, 110-119.	1.2	6
66	Identification of the Phosphatidylserine Binding Site in the C2 Domain that Is Important for PKCÎ± Activation and in Vivo Cell Localization. Biochemistry, 2001, 40, 13898-13905.	1.2	59
67	Correlation between the effect of the anti-neoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine on the membrane and the activity of protein kinase CÎ±. FEBS Journal, 2001, 268, 6369-6378.	0.2	11
68	The C2 domain of protein kinase CÎ± is directly involved in the diacylglycerol-dependent binding of the C1 domain to the membrane. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1487, 246-254.	1.2	25